How will the government’s pressure to cut drug prices affect pharmacy? What will the impact of DIR fee reform be? Will pharmacists get closer to attaining provider status? These are among the questions top chain drug industry executives are considering as they look ahead to 2019.
CARE Pharmacies CEO Mike Wysong was recently featured among the industry’s top business leaders in an article published by Chain Drug Review. This 2019 retail forecast allowed Mike the opportunity to discuss not only the bright future of CARE Pharmacies, but the industry as a whole. You can read Mike’s excerpt below, or by visiting the digital edition of Chain Drug Review.2019 Retail Forecast 1
2019 Retail Forecast 2